A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : Mpro

Search Conditions:
Search Keyword : Mpro
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: Mpro
Appearance Frequency: 987 time(s)
Long forms: 20

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
main protease
(931 times)
Molecular Biology
(153 times)
SARS-CoV-2 (217 times)
COVID-19 (136 times)
MD (119 times)
2003 A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening.
main protease of SARS-CoV-2
(25 times)
Biology
(7 times)
SARS-CoV-2 (4 times)
COVID-19 (2 times)
ARDS (1 time)
2020 Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach.
major protease
(7 times)
Biology
(1 time)
RdRp (3 times)
SARS-CoV-2 (2 times)
ATV (1 time)
2020 Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
main viral protease
(5 times)
Chemistry
(2 times)
COVID-19 (1 time)
hPTP1B (1 time)
2020 Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.
main protease of the coronavirus
(3 times)
Biochemical Phenomena
(1 time)
SARS-CoV-2 (1 time)
2021 SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors.
main SARS-CoV-2 protease 3CLpro
(2 times)
Virology
(1 time)
COVID-19 (2 times)
SARS-CoV-2 (2 times)
2020 A comparative analysis of SARS-CoV-2 antivirals in human airway models characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19.
main 3-chymotrypsin-like cysteine protease
(1 time)
Biotechnology
(1 time)
MD (1 time)
SARS-CoV-2 (1 time)
2020 SARS-CoV-2 Mpro inhibitors: identification of anti-SARS-CoV-2 Mpro compounds from FDA approved drugs.
main cysteine protease from SARS-CoV-2
(1 time)
Drug Design
(1 time)
--- 2022 Perspectives on the design and discovery of alpha-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go?
main protease enzyme
(1 time)
Biology
(1 time)
--- 2022 The Discovery of Small Allosteric and Active Site Inhibitors of the SARS-CoV-2 Main Protease via Structure-Based Virtual Screening and Biological Evaluation.
10  main protease monomer
(1 time)
Biochemistry
(1 time)
--- 2020 Structural stability of the SARS-CoV-2 main protease: Can metal ions affect function?
11  Main Protease of Coronavirus SARS-CoV-2
(1 time)
Pharmacology
(1 time)
--- 2020 Identification of Main Protease of Coronavirus SARS-CoV-2 (Mpro) Inhibitors from Melissa officinalis.
12  main protease protein
(1 time)
Medical Informatics
(1 time)
ACE2 (1 time)
ADME (1 time)
JAK2 (1 time)
2020 Plausible mechanisms explaining the role of cucurbitacins as potential therapeutic drugs against coronavirus 2019.
13  Main Proteases
(1 time)
Biotechnology
(1 time)
MD (1 time)
MM-PBSA (1 time)
NO (1 time)
2020 Potential of NO donor furoxan as SARS-CoV-2 main protease (Mpro) inhibitors: in silico analysis.
14  major protease inhibitors
(1 time)
--- 2022 SMILES-based 2D-QSAR and similarity search for identification of potential new scaffolds for development of SARS-CoV-2 MPRO inhibitors.
15  Metabolite Targeting Viral Protease
(1 time)
Plant Physiological Phenomena
(1 time)
COVID-19 (1 time)
SARS-CoV-2 (1 time)
2021 Carvacrol, a Plant Metabolite Targeting Viral Protease (Mpro) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19.
16  mol, respectively as significant inhibitors of SARS-CoV-2
(1 time)
Virus Diseases
(1 time)
ADMET (1 time)
2021 Target-based drug discovery, ADMET profiling and bioactivity studies of antibiotics as potential inhibitors of SARS-CoV-2 main protease (Mpro).
17  Molecular interaction analysis of protease
(1 time)
Communicable Diseases
(1 time)
--- 2021 Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (Mpro) with pharmacokinetics and toxicological properties.
18  of7-(4-(N-substituted-carbamoyl-methyl)piperazin-1yl)-chalcone in comparison with ciprofloxacin againstSARS-CoV-2main protease
(1 time)
Pharmacology
(1 time)
FQs (1 time)
2021 In vitro inhibition and molecular docking of a new ciprofloxacin-chalcone against SARS-CoV-2 main protease.
19  SARS-CoV-2-main protease
(1 time)
Biotechnology
(1 time)
SARS-CoV-2 (1 time)
2021 Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.
20  SARS-main CoV-2's protease
(1 time)
CADD (1 time)
MDS (1 time)
SBVS (1 time)
2023 In-Silico Lead Druggable Compounds Identification against SARS COVID-19 Main Protease Target from In-House, Chembridge and Zinc Databases by Structure-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulations.